Login to Your Account

Other News To Note

Wednesday, March 14, 2012

• Cytheris SA, of Paris, said a Phase IIa trial (INSPIRE-2) of CYT107 (recombinant interleukin-7) for reconstitution of CD4 T cells in chronic HIV-1 immunological nonresponder patients showed that the drug expanded those cells in the gut mucosa. The companys said it believes the drug may be able to restore the immune system in chronic HIV infection.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription